Unknown

Dataset Information

0

Controlling the pandemic during the SARS-CoV-2 vaccination rollout.

ABSTRACT: There is a consensus that mass vaccination against SARS-CoV-2 will ultimately end the COVID-19 pandemic. However, it is not clear when and which control measures can be relaxed during the rollout of vaccination programmes. We investigate relaxation scenarios using an age-structured transmission model that has been fitted to age-specific seroprevalence data, hospital admissions, and projected vaccination coverage for Portugal. Our analyses suggest that the pressing need to restart socioeconomic activities could lead to new pandemic waves, and that substantial control efforts prove necessary throughout 2021. Using knowledge on control measures introduced in 2020, we anticipate that relaxing measures completely or to the extent as in autumn 2020 could launch a wave starting in April 2021. Additional waves could be prevented altogether if measures are relaxed as in summer 2020 or in a step-wise manner throughout 2021. We discuss at which point the control of COVID-19 would be achieved for each scenario.

SUBMITTER: Viana J 

PROVIDER: S-EPMC8209021 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Controlling the pandemic during the SARS-CoV-2 vaccination rollout.

Viana João J   van Dorp Christiaan H CH   Nunes Ana A   Gomes Manuel C MC   van Boven Michiel M   Kretzschmar Mirjam E ME   Veldhoen Marc M   Rozhnova Ganna G  

Nature communications 20210616 1

There is a consensus that mass vaccination against SARS-CoV-2 will ultimately end the COVID-19 pandemic. However, it is not clear when and which control measures can be relaxed during the rollout of vaccination programmes. We investigate relaxation scenarios using an age-structured transmission model that has been fitted to age-specific seroprevalence data, hospital admissions, and projected vaccination coverage for Portugal. Our analyses suggest that the pressing need to restart socioeconomic a  ...[more]

Similar Datasets

Unknown Ultra-rapid rollout vaccination with BNT162b2 to reduce SARS-CoV-2 infections in the general population.
| S-EPMC9639213 | biostudies-literature
Unknown SARS-CoV-2-Specific Immune Responses in Vaccination and Infection during the Pandemic in 2020-2022.
| S-EPMC10974545 | biostudies-literature
Unknown SARS-CoV-2 Infection Evolution Among Nephrologists During the Pandemic: Clinical Features and Impact of Vaccination.
| S-EPMC9069975 | biostudies-literature
Unknown Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection.
| S-EPMC11567098 | biostudies-literature
Unknown Rapid relaxation of pandemic restrictions after vaccine rollout favors growth of SARS-CoV-2 variants: A model-based analysis.
| S-EPMC8612578 | biostudies-literature
Unknown Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France.
| S-EPMC9148144 | biostudies-literature
Unknown Persistent epigenetic memory of SARS-CoV-2 mRNA vaccination in monocyte-derived macrophages
| S-SCDT-10_1038-S44320-025-00093-6 | biostudies-other
Unknown SARS-CoV-2 Sero-Surveillance in Greece: Evolution over Time and Epidemiological Attributes during the Pre-Vaccination Pandemic Era.
| S-EPMC8871128 | biostudies-literature
Unknown Bronchiolitis, epidemiological changes during the SARS-CoV-2 pandemic.
| S-EPMC8785150 | biostudies-literature
Unknown Management of Anaphylaxis During the SARS-CoV-2 Pandemic.
| S-EPMC7946336 | biostudies-literature